Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Clinical features and survival of patients with T-cell/histiocyte-rich large B-cell lymphoma: analysis of the National Cancer Data Base.

Ollila TA, Reagan JL, Olszewski AJ.

Leuk Lymphoma. 2019 Jul 9:1-8. doi: 10.1080/10428194.2019.1639166. [Epub ahead of print]

PMID:
31287335
2.

Prognostic significance of upfront radiation therapy in patients with multiple myeloma.

Orcutt X, Barth P, Olszewski AJ.

Am J Hematol. 2019 Jul;94(7):E190-E194. doi: 10.1002/ajh.25492. Epub 2019 May 1. No abstract available.

PMID:
31006894
3.
4.

Clonal haematopoiesis of indeterminate potential among cancer survivors exposed to myelotoxic chemotherapy.

Olszewski AJ, Chorzalska AD, Kim AS, Quesenberry PJ, Lopresti ML, Fenton MA, Reagan JL, Butera JN, Sahin I, Hamel C, Robison J, Petersen M, Dubielecka PM.

Br J Haematol. 2019 Aug;186(3):e31-e35. doi: 10.1111/bjh.15861. Epub 2019 Mar 11. No abstract available.

PMID:
30859554
5.

Mogamulizumab: a new tool for management of cutaneous T-cell lymphoma.

Ollila TA, Sahin I, Olszewski AJ.

Onco Targets Ther. 2019 Feb 7;12:1085-1094. doi: 10.2147/OTT.S165615. eCollection 2019. Review.

6.

Outcomes of secondary solid tumor malignancies among patients with myeloma: A population-based study.

Barth P, Castillo JJ, Olszewski AJ.

Cancer. 2019 Feb 15;125(4):550-558. doi: 10.1002/cncr.31853. Epub 2018 Nov 19.

PMID:
30452087
7.

Ibrutinib and Rituximab in Waldenström's Macroglobulinemia.

Olszewski AJ, Castillo JJ.

N Engl J Med. 2018 Nov 15;379(20):1973-4. doi: 10.1056/NEJMc1809505. No abstract available.

PMID:
30439672
8.

Bone marrow-specific loss of ABI1 induces myeloproliferative neoplasm with features resembling human myelofibrosis.

Chorzalska A, Morgan J, Ahsan N, Treaba DO, Olszewski AJ, Petersen M, Kingston N, Cheng Y, Lombardo K, Schorl C, Yu X, Zini R, Pacilli A, Tepper A, Coburn J, Hryniewicz-Jankowska A, Zhao TC, Oancea E, Reagan JL, Liang O, Kotula L, Quesenberry PJ, Gruppuso PA, Manfredini R, Vannucchi AM, Dubielecka PM.

Blood. 2018 Nov 8;132(19):2053-2066. doi: 10.1182/blood-2018-05-848408. Epub 2018 Sep 13.

9.

Prescription Drug Coverage and Outcomes of Myeloma Therapy Among Medicare Beneficiaries.

Olszewski AJ, Dusetzina SB, Trivedi AN, Davidoff AJ.

J Clin Oncol. 2018 Oct 1;36(28):2879-2886. doi: 10.1200/JCO.2018.77.8894. Epub 2018 Aug 16.

10.

Radiation therapy in primary testicular lymphoma: does practice match the standard of care?

Ollila TA, Olszewski AJ.

Leuk Lymphoma. 2019 Feb;60(2):523-526. doi: 10.1080/10428194.2018.1480776. Epub 2018 Jul 3. No abstract available.

PMID:
29966467
11.

Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.

Ollila TA, Olszewski AJ.

Curr Treat Options Oncol. 2018 Jun 21;19(8):38. doi: 10.1007/s11864-018-0555-8. Review.

12.

Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia.

LeBlanc TW, Egan PC, Olszewski AJ.

Blood. 2018 Aug 16;132(7):717-726. doi: 10.1182/blood-2018-03-842575. Epub 2018 May 30.

PMID:
29848484
13.

Time to treatment is an independent prognostic factor in aggressive non-Hodgkin lymphomas.

Olszewski AJ, Ollila T, Reagan JL.

Br J Haematol. 2018 May;181(4):495-504. doi: 10.1111/bjh.15224. Epub 2018 Apr 24.

14.

Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma.

Castillo JJ, Guerrero-Garcia T, Baldini F, Tchernonog E, Cartron G, Ninkovic S, Cwynarski K, Dierickx D, Tousseyn T, Lansigan F, Linnik Y, Mogollon R, Navarro JT, Olszewski AJ, Reagan JL, Fedele P, Gilbertson M, Grigoriadis G, Bibas M.

Br J Haematol. 2019 Feb;184(4):679-682. doi: 10.1111/bjh.15156. Epub 2018 Mar 12. No abstract available.

PMID:
29527667
15.

Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-κB pathways in a model of chronic myeloid leukemia.

Chorzalska A, Ahsan N, Rao RSP, Roder K, Yu X, Morgan J, Tepper A, Hines S, Zhang P, Treaba DO, Zhao TC, Olszewski AJ, Reagan JL, Liang O, Gruppuso PA, Dubielecka PM.

Mol Oncol. 2018 May;12(5):630-647. doi: 10.1002/1878-0261.12186. Epub 2018 Apr 6.

16.

Use of Charity Financial Assistance for Novel Oral Anticancer Agents.

Olszewski AJ, Zullo AR, Nering CR, Huynh JP.

J Oncol Pract. 2018 Apr;14(4):e221-e228. doi: 10.1200/JOP.2017.027896. Epub 2018 Feb 13.

17.

Marrow Hypocellularity, But Not Residual Blast Count or Receipt of Reinduction Chemotherapy, Is Prognostic on Day-14 Assessment in Acute Myeloid Leukemia Patients With Morphologic Residual Disease.

Ollila TA, Olszewski AJ, Butera JN, Quesenberry MI, Quesenberry PJ, Reagan JL.

Clin Lymphoma Myeloma Leuk. 2018 Mar;18(3):204-209. doi: 10.1016/j.clml.2018.01.007. Epub 2018 Jan 31.

PMID:
29433979
18.

Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base.

Qunaj L, Castillo JJ, Olszewski AJ.

Leuk Lymphoma. 2018 Jun;59(6):1375-1383. doi: 10.1080/10428194.2017.1387912. Epub 2017 Oct 11.

PMID:
29019447
19.

Late infections and secondary malignancies after bendamustine/rituximab or RCHOP/RCVP chemotherapy for B-cell lymphomas.

Olszewski AJ, Reagan JL, Castillo JJ.

Am J Hematol. 2018 Jan;93(1):E1-E3. doi: 10.1002/ajh.24921. Epub 2017 Oct 19. No abstract available.

20.

Comparative outcomes of immunochemotherapy regimens in Waldenström macroglobulinaemia.

Olszewski AJ, Chen C, Gutman R, Treon SP, Castillo JJ.

Br J Haematol. 2017 Oct;179(1):106-115. doi: 10.1111/bjh.14828. Epub 2017 Jul 5.

PMID:
28677830
21.

Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.

Olszewski AJ, Dusetzina SB, Eaton CB, Davidoff AJ, Trivedi AN.

J Clin Oncol. 2017 Oct 10;35(29):3306-3314. doi: 10.1200/JCO.2017.72.2447. Epub 2017 May 25.

22.

Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.

Landsburg DJ, Falkiewicz MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Ilizaliturri F, Reddy NM, Singavi A, Fenske TS, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD.

J Clin Oncol. 2017 Jul 10;35(20):2260-2267. doi: 10.1200/JCO.2017.72.2157. Epub 2017 May 5.

23.

Informed consent in oncology clinical trials: A Brown University Oncology Research Group prospective cross-sectional pilot study.

Schumacher A, Sikov WM, Quesenberry MI, Safran H, Khurshid H, Mitchell KM, Olszewski AJ.

PLoS One. 2017 Feb 24;12(2):e0172957. doi: 10.1371/journal.pone.0172957. eCollection 2017.

24.

Long-Term Exposure to Imatinib Mesylate Downregulates Hippo Pathway and Activates YAP in a Model of Chronic Myelogenous Leukemia.

Chorzalska A, Kim JF, Roder K, Tepper A, Ahsan N, Rao RSP, Olszewski AJ, Yu X, Terentyev D, Morgan J, Treaba DO, Zhao TC, Liang O, Gruppuso PA, Dubielecka PM.

Stem Cells Dev. 2017 May 1;26(9):656-677. doi: 10.1089/scd.2016.0262. Epub 2017 Feb 27.

25.

Variation in the use of up-front chemotherapy for indolent B-cell lymphomas and chronic lymphocytic leukemia.

Fallah J, Olszewski AJ.

Hematol Oncol. 2017 Dec;35(4):921-924. doi: 10.1002/hon.2382. Epub 2016 Dec 16. No abstract available.

PMID:
27982452
26.

Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database.

Fallah J, Qunaj L, Olszewski AJ.

Blood Adv. 2016 Nov 30;1(2):112-121. doi: 10.1182/bloodadvances.2016000927. eCollection 2016 Dec 13.

27.

Blunt tools, burning questions: using cancer registry data to study relapsed/refractory lymphoma.

Olszewski AJ.

Leuk Lymphoma. 2017 May;58(5):1013-1015. doi: 10.1080/10428194.2016.1262035. Epub 2016 Nov 28. No abstract available.

PMID:
27892747
28.

Adjuvant Therapy for Resected Gallbladder Cancer: Analysis of the National Cancer Data Base.

Mantripragada KC, Hamid F, Shafqat H, Olszewski AJ.

J Natl Cancer Inst. 2016 Oct 5;109(2). pii: djw202. Print 2017 Feb.

PMID:
27707843
29.

Formulating a novel prognostic index for diffuse large B-cell lymphoma: T cells break the SILence.

Olszewski AJ.

Leuk Lymphoma. 2016 Dec;57(12):2733-2735. Epub 2016 Aug 11. No abstract available.

PMID:
27686108
30.

Increased risk of axial fractures in patients with untreated chronic lymphocytic leukemia: a population-based analysis.

Olszewski AJ, Gutman R, Eaton CB.

Haematologica. 2016 Dec;101(12):e488-e491. Epub 2016 Aug 4. No abstract available.

31.

Risk Factors for Early Death After Rituximab-Based Immunochemotherapy in Older Patients With Diffuse Large B-Cell Lymphoma.

Olszewski AJ, Mantripragada KC, Castillo JJ.

J Natl Compr Canc Netw. 2016 Sep;14(9):1121-9.

PMID:
27587624
32.

Evolution of Management and Outcomes in Waldenström Macroglobulinemia: A Population-Based Analysis.

Olszewski AJ, Treon SP, Castillo JJ.

Oncologist. 2016 Nov;21(11):1377-1386. doi: 10.1634/theoncologist.2016-0126. Epub 2016 Jul 29.

33.

Human immunodeficiency virus-associated lymphomas in the antiretroviral therapy era: Analysis of the National Cancer Data Base.

Olszewski AJ, Fallah J, Castillo JJ.

Cancer. 2016 Sep 1;122(17):2689-97. doi: 10.1002/cncr.30112. Epub 2016 Jun 23.

34.

Clinical Trial Accrual Targeting Genomic Alterations After Next-Generation Sequencing at a Non-National Cancer Institute-Designated Cancer Program.

Mantripragada KC, Olszewski AJ, Schumacher A, Perez K, Birnbaum A, Reagan JL, Mega A, Khurshid H, Bartley C, Lombardo A, Rossiter R, Papa A, Bakalarski P, Safran H.

J Oncol Pract. 2016 Apr;12(4):e396-404. doi: 10.1200/JOP.2015.008433. Epub 2016 Feb 23.

PMID:
26907448
35.

Survival Claims From Observational Data on Cancer Therapy.

Olszewski AJ, Falah J, Castillo JJ.

J Clin Oncol. 2016 Apr 20;34(12):1425-7. doi: 10.1200/JCO.2015.64.7644. Epub 2016 Feb 16. No abstract available.

PMID:
26884574
36.

Outcomes of HIV-associated Hodgkin lymphoma in the era of antiretroviral therapy.

Olszewski AJ, Castillo JJ.

AIDS. 2016 Mar 13;30(5):787-96. doi: 10.1097/QAD.0000000000000986.

PMID:
26730566
37.

Limits of registry data to understand survival disparities in lymphoma.

Olszewski AJ.

Lancet Haematol. 2015 Nov;2(11):e459-60. doi: 10.1016/S2352-3026(15)00188-X. Epub 2015 Oct 23. No abstract available.

PMID:
26686253
38.

Health Insurance-Related Disparities in Lymphoma Survival Are Partly Mediated by Baseline Clinical Factors.

Olszewski AJ, Foran JM.

Oncologist. 2015 Oct;20(10):1223-4. doi: 10.1634/theoncologist.2015-0228. Epub 2015 Oct 2. No abstract available.

39.

Disparities in conditional net survival among non-Hodgkin lymphoma survivors: a population-based analysis.

Migdady Y, Salhab M, Dang NH, Markham MJ, Olszewski AJ.

Leuk Lymphoma. 2016;57(3):676-84. doi: 10.3109/10428194.2015.1102246. Epub 2015 Dec 23.

PMID:
26428541
40.

Disparate survival trends in histologic subtypes of metastatic non-small cell lung cancer: a population-based analysis.

Olszewski AJ, Ali S, Witherby SM.

Am J Cancer Res. 2015 Jun 15;5(7):2229-40. eCollection 2015.

41.

Surgical management of metastatic colon cancer: A population-based analysis.

Khan H, Khan N, Ahmad A, Olszewski AJ, Somasundar P.

J Geriatr Oncol. 2015 Nov;6(6):446-53. doi: 10.1016/j.jgo.2015.08.002. Epub 2015 Aug 18.

PMID:
26296910
42.

Small Bowel Adenocarcinoma as the Cause of Gastrointestinal Bleeding in Celiac Disease: A Rare Malignancy in a Common Disease.

Fallah J, Afari ME, Cordova AC, Olszewski AJ, Minami T.

Case Rep Oncol Med. 2015;2015:865383. doi: 10.1155/2015/865383. Epub 2015 Jul 28.

43.

Race-specific features and outcomes of nodular lymphocyte-predominant Hodgkin lymphoma: Analysis of the National Cancer Data Base.

Olszewski AJ, Shrestha R, Cook NM.

Cancer. 2015 Oct 1;121(19):3472-80. doi: 10.1002/cncr.29527. Epub 2015 Jul 6.

44.

Validation of clinical prognostic indices for diffuse large B-cell lymphoma in the National Cancer Data Base.

Olszewski AJ, Winer ES, Castillo JJ.

Cancer Causes Control. 2015 Aug;26(8):1163-72. doi: 10.1007/s10552-015-0610-8. Epub 2015 Jun 9.

PMID:
26054914
45.

Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database.

Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP.

Am J Hematol. 2015 Aug;90(8):696-701. doi: 10.1002/ajh.24052. Epub 2015 May 28.

46.

Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database.

Castillo JJ, Olszewski AJ, Hunter ZR, Kanan S, Meid K, Treon SP.

Cancer. 2015 Jul 1;121(13):2230-6. doi: 10.1002/cncr.29334. Epub 2015 Mar 10.

47.

Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis.

Shafqat H, Ali S, Salhab M, Olszewski AJ.

Dis Colon Rectum. 2015 Mar;58(3):294-303. doi: 10.1097/DCR.0000000000000298.

PMID:
25664707
48.

Treatment selection and outcomes in early-stage classical Hodgkin lymphoma: analysis of the National Cancer Data Base.

Olszewski AJ, Shrestha R, Castillo JJ.

J Clin Oncol. 2015 Feb 20;33(6):625-33. doi: 10.1200/JCO.2014.58.7543. Epub 2015 Jan 12.

PMID:
25584010
49.

Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database.

Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP.

Br J Haematol. 2015 Apr;169(1):81-9. doi: 10.1111/bjh.13264. Epub 2014 Dec 18.

PMID:
25521528
50.

Lymph node involvement in colon cancer patients decreases with age; a population based analysis.

Khan H, Olszewski AJ, Somasundar P.

Eur J Surg Oncol. 2014 Nov;40(11):1474-80. doi: 10.1016/j.ejso.2014.06.002. Epub 2014 Jul 3.

PMID:
25027280

Supplemental Content

Loading ...
Support Center